There is a strong rationale for lysyl oxidase inhibitors as a therapeutic approach in mesothelioma due to their ant-fibrotic mechanisms [152,153], synergism with chemotherapies [1], and modulation of EMT in mesothelioma [154,155]. Here, LOX is linked to mesothelioma.